162 related articles for article (PubMed ID: 34043207)
21. Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan.
Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
Clin Genitourin Cancer; 2018 Jun; 16(3):219-225. PubMed ID: 29274813
[TBL] [Abstract][Full Text] [Related]
22. PSA nadir and time to PSA nadir during initial androgen deprivation therapy as prognostic factors in metastatic castration-resistance prostate cancer patients treated with docetaxel.
Shi X; Pei X; Fan J; Liu T; Zhang D; Yang T; Wu K; He D; Li L
Andrologia; 2021 May; 53(4):e13916. PubMed ID: 33591598
[TBL] [Abstract][Full Text] [Related]
23. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
[TBL] [Abstract][Full Text] [Related]
24. Second-line treatment options in metastatic castration-resistant prostate cancer after progression on first-line androgen-receptor targeting therapies: A systematic review and Bayesian network analysis.
Xiong X; Zhang S; Zheng W; Liao X; Yang J; Xu H; Hu S; Wei Q; Yang L
Crit Rev Oncol Hematol; 2024 Apr; 196():104286. PubMed ID: 38316286
[TBL] [Abstract][Full Text] [Related]
25. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN
Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831
[TBL] [Abstract][Full Text] [Related]
26. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China.
Pei XQ; He DL; Tian G; Lv W; Jiang YM; Wu DP; Fan JH; Wu KJ
Int Urol Nephrol; 2017 Apr; 49(4):629-635. PubMed ID: 28161841
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
[TBL] [Abstract][Full Text] [Related]
29. Clinical Impact of the Number of Treatment Cycles in First-Line Docetaxel for Patients With Metastatic Castration-Resistant Prostate Cancer.
Kongsted P; Svane IM; Lindberg H; Sengeløv L
Clin Genitourin Cancer; 2017 Apr; 15(2):e281-e287. PubMed ID: 27692811
[TBL] [Abstract][Full Text] [Related]
30. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
[TBL] [Abstract][Full Text] [Related]
32. Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC).
Ryan CJ; Dutta S; Kelly WK; Russell C; Small EJ; Morris MJ; Taplin ME; Halabi S;
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):66-73. PubMed ID: 31053766
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of docetaxel and prednisolone chemotherapy in very elderly men with metastatic castration-resistant prostate cancer (mCRPC) in real world: a single institute experience.
Wang KY; Ma L; Zhang LL; Hu YC; Jiang JH; Ma Q
Ann Palliat Med; 2021 Feb; 10(2):1438-1444. PubMed ID: 33081478
[TBL] [Abstract][Full Text] [Related]
34. Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents.
Angelergues A; Efstathiou E; Gyftaki R; Wysocki PJ; Lainez N; Gonzalez I; Castellano DE; Ozguroglu M; Carbonero IG; Flechon A; Borrega P; Guillot A; Balea BC; Le Moulec S; Esteban E; Munarriz J; Rubio G; Birtle AJ; Delanoy N; Bellmunt J; Oudard S
Clin Genitourin Cancer; 2018 Aug; 16(4):e777-e784. PubMed ID: 29550200
[TBL] [Abstract][Full Text] [Related]
35. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials.
Templeton AJ; Vera-Badillo FE; Wang L; Attalla M; De Gouveia P; Leibowitz-Amit R; Knox JJ; Moore M; Sridhar SS; Joshua AM; Pond GR; Amir E; Tannock IF
Ann Oncol; 2013 Dec; 24(12):2972-7. PubMed ID: 24126362
[TBL] [Abstract][Full Text] [Related]
36. Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy.
Halabi S; Armstrong AJ; Sartor O; de Bono J; Kaplan E; Lin CY; Solomon NC; Small EJ
J Clin Oncol; 2013 Nov; 31(31):3944-50. PubMed ID: 24101043
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of cabazitaxel in fourth or later line of therapy in metastatic castration-resistant prostate cancer: Multi-institutional real-world experience in Germany.
Wenzel M; Borkowetz A; Lieb V; Hoffmann MA; Borgmann H; Höfner T; Dotzauer R; Neuberger M; Worst TS; von Hardenberg J; Linxweiler J; Klümper N
Urol Oncol; 2022 Dec; 40(12):538.e7-538.e14. PubMed ID: 36244915
[TBL] [Abstract][Full Text] [Related]
38. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Massard C; Mateo J; Loriot Y; Pezaro C; Albiges L; Mehra N; Varga A; Bianchini D; Ryan CJ; Petrylak DP; Attard G; Shen L; Fizazi K; de Bono J
Ann Oncol; 2017 Jan; 28(1):90-95. PubMed ID: 28039155
[TBL] [Abstract][Full Text] [Related]
39. An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progression.
Miyazawa Y; Sekine Y; Shimizu N; Takezawa Y; Nakamura T; Miyao T; Nakayama H; Kurihara S; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Suzuki K
Prostate; 2019 Sep; 79(12):1462-1470. PubMed ID: 31334872
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer.
Emamekhoo H; Barata PC; Edwin NC; Woo KM; Grivas P; Garcia JA
Clin Genitourin Cancer; 2018 Dec; 16(6):429-436. PubMed ID: 30236961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
